Molecular proximity orchestrates biological function, and blocking existing proximities is an
established therapeutic strategy. By contrast, strengthening or creating neoproximity with …

The cancer genomics revolution has served up a plethora of promising and challenging
targets for the drug discovery community. The field of targeted protein degradation (TPD) …

Targeted protein degradation with molecular glue degraders has arisen as a powerful
therapeutic modality for eliminating classically undruggable disease-causing proteins …

Targeted protein degradation relies on small molecules that induce new protein–protein
interactions between targets and the cellular protein degradation machinery. Most of these …

Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Targeted protein degradation (TPD) by PROTAC (proteolysis-targeting chimera) and
molecular glue small molecules is an emerging therapeutic strategy. To expand the roster of …

The concept of induced protein degradation by small molecules has emerged as a
promising therapeutic strategy that is particularly effective in targeting proteins previously …

Targeted protein degradation is a pharmacological modality that is based on the induced
proximity of an E3 ubiquitin ligase and a target protein to promote target ubiquitination and …

Targeted protein degradation has recently emerged as a novel option in drug discovery.
Natural protein half-life is expected to affect the efficacy of degrading agents, but to what …

Conditional protein degradation tags (degrons) are usually> 100 amino acids long or are
triggered by small molecules with substantial off-target effects, thwarting their use as specific …